without special characters or encryption.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: March 6, 1996.

Roberta Katson,

Director, Division of Information Resource Management Services.

[FR Doc. 96–6189 Filed 3–13–96; 8:45 am]

BILLING CODE 4184–01–M

Proposed Collection; Comment Request

Proposed Project(s):

Title: Jobs Opportunity Basic Skills (JOBS) Participation Rate Quarterly Report.

OMB No.: 0970–0098.

Description: The information received from this collection will provide ACF the information to determine if each State has met the required JOBS participation rates and adjust the FFP rate accordingly. State must establish that the specified percentage of those required to participate in the JOBS program actually participate. The routine collection of participation rate data also provides ACF with sufficient information to adequately respond to inquires from Congress and other interested parties regarding nationwide JOBS participation rates.

Respondents: State governments

ANNUAL BURDEN ESTIMATES

Instrument	No. of respondents	No. of responses per respondent	Average burden hours per response	Total burden hours
ACF–103	54	4	12	2,592
Estimated Total Annual Burden Hours: 2,592.				

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to The Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by title.

In addition, requests of copies may be made and comments forwarded to the Reports Clearance Officer over the Internet by sending a message to rkatson@acf.dhhs.gov. Internet messages must be submitted as an ASCII file without special characters or encryption.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: March 6, 1996

Roberta Katson,

Director, Division of Information Resource Management Services.

[FR Doc. 96–6190 Filed 3–13–96; 8:45 am]

BILLING CODE 4194–01–M

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made final findings of scientific misconduct in the following case:

Gail L. Daubert, R.N., Northwestern University: Based on an investigation conducted by its Division of Research Investigations, ORI found that Gail Daubert, R.N., while serving as clinic coordinator for the Collaborative Ocular Melanoma Study (COMS) at Northwestern University, committed scientific misconduct by falsifying clinical trial data. The multicenter COMS involves research on the treatment of choroidal melanoma, a rare form of eye cancer. It is supported by the National Eye Institute. The study is still ongoing, and no results have been published.

ORI found that Ms. Daubert falsified 211 data items, including falsely stating that a radiation oncologist had evaluated patients prior to randomization, falsely reporting laboratory blood test results were normal when they were abnormal, falsely reporting that dates for patient visits or procedures had been performed within the specified protocol window when the actual date was outside the protocol window, and falsely reporting that a COMS certified examiner had performed an evaluation or procedure when a noncertified examiner had performed the task.

Ms. Daubert has entered into a Voluntary Exclusion Agreement with ORI in which she does not admit to any acts of scientific misconduct, but she has agreed to exclude herself voluntarily, for the three (3) year period beginning March 4, 1996, from:

(1) contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government, as defined in 45 CFR Part 76 and 48 CFR Subparts 9.4 and 309.4 (Debarment Regulations); and

(2) serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

The above voluntary exclusion, however, shall not apply to Ms. Daubert's future training or practice of clinical medicine as a nurse, unless that practice involves research or research

training, or to Ms. Daubert's participation in or eligibility for any Federal program relating to student loans, education grants, or educational assistance of any type or kind, for which she would otherwise be qualified to receive or be considered to receive (educational assistance), unless that educational assistance involves research or research training.

FOR FURTHER INFORMATION CONTACT: Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852.

Lyle W. Bivens,

Director, Office of Research Integrity.

[FR Doc. 96–6026 Filed 3–13–96; 8:45 am]

BILLING CODE 4160–17–P

Agency for Health Care Policy and Research

Health Care Policy and Research Emphasis Panel; Notice of Meeting

In accordance with section 10(a) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2) announcement is made of the following special emphasis panel scheduled to meet during the month of March 1996:

Name: Health Care Policy and Research Special Emphasis Panel

Date and Time: March 26, 1996, 1:30 p.m.

Place: Agency for Health Care Policy and Research, 2101 E. Jefferson Street, Suite 400, Rockville, MD 20852.

Open March 26, 1996, 1:30 p.m. to 1:45 p.m.

Closed for remainder of meeting.

Purpose: This Panel is charged with conducting review of grant applications for Conference Support.

Agenda: The open session of the meeting on March 26 from 1:30 p.m. to 1:45 p.m. will be devoted to a business meeting covering administrative matters. During the closed session, the committee will be reviewing grant applications for Conference Support. In accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C., 552b(c)(6), the Administrator, AHCPR, has made a formal determination that this latter session will be closed because the discussions are likely to reveal personal information concerning individuals associated with the grant applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a roster of members or other relevant information should contact Linda Blankenbaker, Agency for Health Care Policy and Research, Suite 400, 2101 East Jefferson Street, Rockville, Maryland 20852, Telephone (301) 594–1438.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: March 7, 1996.

Clifton R. Gaus,

Administrator.

[FR Doc. 96–6072 Filed 3–13–96; 8:45 am]

BILLING CODE 4160–90–M

Centers for Disease Control and Prevention

Advisory Committee for Injury Prevention and Control (ACIPC) and the ACIPC Family and Intimate Violence Prevention Subcommittee Meetings: Change of Location

FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: 61 FR 7110—dated February 26, 1996.

SUMMARY: Notice is given that the meeting location for the Advisory Committee for Injury Prevention and Control (ACIPC) and the ACIPC Family and Intimate Violence Prevention Subcommittee of the Centers for Disease Control and Prevention (CDC) has changed. The meeting times, dates, status, purpose, and matters to be discussed announced in the original notice remain unchanged.

ORIGINAL LOCATION: Wyndham Garden Hotel-Atlanta Buckhead, 3340 Peachtree Road, NE, Atlanta, Georgia 30326.

NEW LOCATION: Crowne Plaze Ravinia, 4355 Ashford-Dunwoody Road, Atlanta, Georgia 30346.

CONTACT PERSON FOR MORE INFORMATION: Mr. Thomas A. Bartenfeld, Acting Executive Secretary, ACIPC, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway, NE, M/S K02, Atlanta, Georgia 30341–3724, telephone 770/488–4230.

Dated: March 8, 1996.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–6068 Filed 3–13–96; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 96N–0085]

Drug Export; ACEL-IMUNE® Diphtheria-Tetanus Toxoid (Acellular) Pertussis Vaccine Adsorbed

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that American Cyanamid Co., Lederle-Praxis Biologicals Div. has filed an application requesting approval for the export of the human biological product ACEL-IMUNE® Diphtheria-Tetanus Toxoid (Acellular) Pertussis Vaccine Adsorbed to the Federal Republic of Germany.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Cathy E. Conn, Center for Biologics Evaluation and Research (HFM–610), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–2006.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of human biological products that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that American Cyanamid Co., Lederle-Praxis Biologicals Div., 401 North Middletown Rd., Pearl River, NY 10965, has filed an application requesting approval for the export of the human biological product ACEL-IMUNE® Diphtheria-Tetanus Toxoid (Acellular) Pertussis Vaccine Adsorbed to the Federal Republic of Germany. The ACEL-IMUNE® Diphtheria-Tetanus Toxoid (Acellular) Pertussis Vaccine Adsorbed is for immunization against diphtheria, tetanus and pertussis (whooping cough) from 15 months to 6 years of age. The application was received and filed in the Center for Biologics Evaluation and Research on February 23, 1996, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch